Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Name: Eulerpool
Brand: Eulerpool Research Systems
Availability: InStock
Rating: 4,9 (755 reviews)

Subscribe for $2

Overview

Profile

Eterna Therapeutics stock price, quote, forecast and news
stock price, forecast, news, chart, split, dividend and analysis Eterna Therapeutics ariva, Eterna Therapeutics onvista, Eterna Therapeutics finanzen.net, Eterna Therapeutics aktienfinder, Eterna Therapeutics marketscreener, Eterna Therapeutics marketwatch, Eterna Therapeutics bloomberg, Eterna Therapeutics handelsblatt, Eterna Therapeutics wiwo, Eterna Therapeutics forum

ERNA

US1140822099

Currency:

Price

1.84

Today +/-

+0.12

Today %

+7.19 %

Ticker
ERNA

ISIN
US1140822099

Eterna Therapeutics stock price

Weekly

Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Eterna Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Eterna Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Eterna Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Eterna Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Eterna Therapeutics Stock Price History

Date	Eterna Therapeutics Price
8/8/2024	1.84 undefined
8/7/2024	1.71 undefined
8/6/2024	1.68 undefined
8/5/2024	1.66 undefined
8/2/2024	1.78 undefined
8/1/2024	1.72 undefined
7/31/2024	1.81 undefined
7/30/2024	1.81 undefined
7/29/2024	1.81 undefined
7/26/2024	1.81 undefined
7/25/2024	1.80 undefined
7/24/2024	1.92 undefined
7/23/2024	2.00 undefined
7/22/2024	2.00 undefined
7/19/2024	2.15 undefined
7/18/2024	2.13 undefined
7/17/2024	2.02 undefined
7/16/2024	2.08 undefined
7/15/2024	2.09 undefined
7/12/2024	2.05 undefined
7/11/2024	1.94 undefined

Eterna Therapeutics Revenue, EBIT, Net Income US1140822099 ·

3 years
5 years
10 years
25 Years
Max

Revenue

EBIT

Net Income

Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Eterna Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eterna Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eterna Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eterna Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eterna Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eterna Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eterna Therapeutics’s growth potential.

Eterna Therapeutics Revenue, EBIT and net profit per share

Date	Eterna Therapeutics Revenue	Eterna Therapeutics EBIT	Eterna Therapeutics Net Income
2023	68,000 undefined	-20.68 M undefined	-21.68 M undefined
2022	0 undefined	-27.23 M undefined	-24.6 M undefined
2021	0 undefined	-27.43 M undefined	-122.56 M undefined
2020	5.8 M undefined	-5.4 M undefined	-4.43 M undefined
2019	19.81 M undefined	-1.21 M undefined	-2.06 M undefined
2018	23.34 M undefined	460,000 undefined	-280,000 undefined
2017	21.27 M undefined	-1.4 M undefined	-1.09 M undefined
2016	22.31 M undefined	-2.28 M undefined	-2.92 M undefined
2015	24.52 M undefined	-6.6 M undefined	-7.23 M undefined
2014	26.05 M undefined	-4.07 M undefined	-5.03 M undefined
2013	23.75 M undefined	-890,000 undefined	-1.05 M undefined
2012	24.06 M undefined	-1.05 M undefined	-1 M undefined
2011	23.87 M undefined	-3.12 M undefined	-3.42 M undefined
2010	25.31 M undefined	-90,000 undefined	-400,000 undefined
2009	25.81 M undefined	-1.34 M undefined	-1.5 M undefined
2008	27.5 M undefined	-5.61 M undefined	-6.47 M undefined
2007	30.54 M undefined	-2.91 M undefined	-5.03 M undefined
2006	32.99 M undefined	1.23 M undefined	-4.77 M undefined
2005	30.75 M undefined	80,000 undefined	-2.02 M undefined
2004	26.28 M undefined	-2.4 M undefined	-4.98 M undefined

	Revenue	EBIT	Net Income
2004	26.28 M USD	-2.4 M USD	-4.98 M USD
2005	30.75 M USD	80,000 USD	-2.02 M USD
2006	32.99 M USD	1.23 M USD	-4.77 M USD
2007	30.54 M USD	-2.91 M USD	-5.03 M USD
2008	27.5 M USD	-5.61 M USD	-6.47 M USD
2009	25.81 M USD	-1.34 M USD	-1.5 M USD
2010	25.31 M USD	-90,000 USD	-400,000 USD
2011	23.87 M USD	-3.12 M USD	-3.42 M USD
2012	24.06 M USD	-1.05 M USD	-1 M USD
2013	23.75 M USD	-890,000 USD	-1.05 M USD
2014	26.05 M USD	-4.07 M USD	-5.03 M USD
2015	24.52 M USD	-6.6 M USD	-7.23 M USD
2016	22.31 M USD	-2.28 M USD	-2.92 M USD
2017	21.27 M USD	-1.4 M USD	-1.09 M USD
2018	23.34 M USD	460,000 USD	-280,000 USD
2019	19.81 M USD	-1.21 M USD	-2.06 M USD
2020	5.8 M USD	-5.4 M USD	-4.43 M USD
2021	0 USD	-27.43 M USD	-122.56 M USD
2022	0 USD	-27.23 M USD	-24.6 M USD
2023	68,000 USD	-20.68 M USD	-21.68 M USD

Eterna Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Simple
Expanded

Income Statement
Balance Sheet
Cashflow

REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (k)EBIT MARGIN (%)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS

1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
0	0	0	1	2	3	3	5	10	17	16	20	25	25	24	23	22	22	25	29	26	30	32	30	27	25	25	23	24	23	26	24	22	21	23	19	5	0	0	0
-	-	-	-	100.00	50.00	-	66.67	100.00	70.00	-5.88	25.00	25.00	-	-4.00	-4.17	-4.35	-	13.64	16.00	-10.34	15.38	6.67	-6.25	-10.00	-7.41	-	-8.00	4.35	-4.17	13.04	-7.69	-8.33	-4.55	9.52	-17.39	-73.68	-	-	-
-	-	-	-300.00	-100.00	-	-	-20.00	-20.00	-5.88	62.50	80.00	76.00	76.00	58.33	52.17	45.45	63.64	60.00	62.07	65.38	66.67	68.75	70.00	70.37	76.00	76.00	78.26	70.83	69.57	53.85	45.83	63.64	66.67	65.22	63.16	40.00	-	-	-
-1	-2	-2	-3	-2	0	0	-1	-2	-1	10	16	19	19	14	12	10	14	15	18	17	20	22	21	19	19	19	18	17	16	14	11	14	14	15	12	2	0	0	0
-1,000	-2,000	-2,000	-3,000	-2,000	0	0	-1,000	-2,000	-1,000	0	-3,000	-15,000	-12,000	-3,000	-3,000	-6,000	-2,000	-1,000	-2,000	-2,000	0	1,000	-2,000	-5,000	-1,000	0	-3,000	-1,000	0	-4,000	-6,000	-2,000	-1,000	0	-1,000	-5,000	-27,000	-27,000	-20,000
-	-	-	-300.00	-100.00	-	-	-20.00	-20.00	-5.88	-	-15.00	-60.00	-48.00	-12.50	-13.04	-27.27	-9.09	-4.00	-6.90	-7.69	-	3.13	-6.67	-18.52	-4.00	-	-13.04	-4.17	-	-15.38	-25.00	-9.09	-4.76	-	-5.26	-100.00	-	-	-
-1,000	-2,000	-2,000	-4,000	-3,000	-1,000	-1,000	1,000	-2,000	-1,000	0	-3,000	-22,000	-12,000	-2,000	-2,000	-9,000	-3,000	-2,000	-2,000	-4,000	-2,000	-4,000	-5,000	-6,000	-1,000	0	-3,000	-1,000	-1,000	-5,000	-7,000	-2,000	-1,000	0	-2,000	-4,000	-122,000	-24,000	-21,000
-	100.00	-	100.00	-25.00	-66.67	-	-200.00	-300.00	-50.00	-	-	633.33	-45.45	-83.33	-	350.00	-66.67	-33.33	-	100.00	-50.00	100.00	25.00	20.00	-83.33	-	-	-66.67	-	400.00	40.00	-71.43	-50.00	-	-	100.00	2,950.00	-80.33	-12.50
0	0	0	0	0	0	0	0	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.02	0.02	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.04	0.04	0.05	0.05	0.06	0.07	0.07	0.07	2.17	3.05	5.31
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Details

Keystats

ⓘ

Revenue and Growth

The Eterna Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Eterna Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT ASSETS (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-TERM INVESTMENTS (M)LONG-T. INVEST. (M)LONG-TERM RECEIVABLES (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)OTHER EQUITY (M)UNREALIZED GAINS/LOSSES (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIABILITIES (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)SHORT-TERM DEBTS (M)SHORT-TERM PORTION OF LONG-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM RECEIVABLES (M)SHORT-TERM REC. (M)LONG-TERM LIABILITIES (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIABILITIES (M)OTHER LIAB. (M)LONG-TERM LIABILITIES (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)

1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

0.12	0.03	0.2	0.05	0.22	0.26	2.39	5.35	10.76	4.65	8.06	6.58	4.76	4.56	1.98	2.46	1.47	0.76	2.69	7.01	6.24	9.11	10.54	3.42	3.82	4.09	1.37	2.72	5.46	7.19	3.22	5.69	3.38	2.54	3.21	0.78	16.99	11.45	7.58
0	0.01	0.33	0.25	0.27	0.26	0.62	1.3	4.19	6.58	4.52	2.23	2.72	2.47	2.54	1.72	1.41	2.01	2.32	3.41	2.15	1.87	1.35	0.64	0.61	0.55	0.75	0.61	0.64	2.19	0.92	0.93	0.71	1.14	1.2	0.12	0.68	0.95	0.43
0	0	0	0	0	0	0	0	0	0	1.03	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.12	2.15	1.68	1.11	0.9	1.01	1.49	3.76	4.63	5.62	0	0	0	0	0	0	0.24	0.4	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.15	0.11	0.14	0.2	0.31	0.28	0.87	4.2	2.98	6.78	1.85	0.9	1.1	1.87	1.63	1.34	1.17	1.29	2.69	8.68	4.01	1.02	0.61	0.63	0.59	0.67	0.9	1.82	5.5	4.97	4.05	5.55	3.11	1.67	0.84	1.1	1.28	1.6
0.12	0.31	2.79	2.12	1.8	1.73	4.3	9.01	22.91	18.84	26.01	10.66	8.38	8.13	6.39	5.81	4.22	4.18	6.7	13.51	17.07	14.99	12.91	4.67	5.06	5.23	2.79	4.23	7.92	14.88	9.11	10.67	9.64	6.79	6.08	1.74	18.77	13.68	9.6
0.14	0.23	0.19	0.18	0.16	0.13	0.22	0.34	0.85	1.41	2.02	10.1	7.97	7.25	10.47	11.96	8.03	5.14	4.4	6.45	7.81	5.92	4.1	3.43	3.81	3.64	4.26	3.78	3.24	3.4	3.92	3.1	3.68	4.67	4.92	0.54	4.24	1.33	33.27
0	0	0	0	0	0	0	0	0	1.98	2.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.49	0	0
0	0	0	0	0	0	0	0	0	3.26	3.44	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	2.19	3.15	4.4	3.7	1.14	0.14	0.41	0.67	0.86	5.48	4.77	2.73	2.37	1.21	1.05	2.96	2.12	2.17	2.56	2.48	1.76	1.02	1	1.46	2.02	1.92	1.36	5.99	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.23	3.49	3.66	0.97	0.97	1.29	1.03	1.2	1.26	1.24	1.27	1.18	1.08	0.91	0.94	1	0.67	0.7	0	2.04	2.04	2.04
0.02	0.02	0.09	0.05	0.08	0.02	0.07	0.83	3.49	3.56	4.4	3.35	0.21	0.25	0.29	0.65	0.46	0.43	0.56	1	1.43	2.27	1.36	1.49	1.27	0.88	1.19	0.82	0.65	1.15	1.45	1	0.79	0.73	0.52	0.12	0	5.23	4.22
0.16	0.25	0.28	0.23	0.24	0.15	0.29	1.17	4.34	12.4	15.21	17.85	11.88	8.64	10.9	13.02	9.16	6.66	13.93	15.88	12.94	11.53	7.96	7	9.24	7.9	8.86	8.43	7.55	7.39	7.3	6.04	6.93	8.09	8.06	2.02	12.76	8.6	39.53
0.28	0.56	3.07	2.35	2.04	1.88	4.59	10.18	27.25	31.24	41.22	28.51	20.26	16.77	17.29	18.83	13.38	10.84	20.63	29.39	30.01	26.52	20.87	11.67	14.3	13.13	11.65	12.66	15.47	22.27	16.41	16.71	16.57	14.88	14.14	3.76	31.53	22.28	49.13

80	90	90	120	150	190	60	70	90	100	110	120	120	140	150	180	190	200	240	260	270	270	280	280	300	300	310	360	390	460	460	10	10	10	10	20	260	30	28
2.02	2.96	3.19	6.55	7.49	7.86	19.03	26.01	43.5	44.6	56.75	59.58	70.54	70.73	66.55	78.15	80.64	81.21	95.24	109.01	109.86	111.62	112.94	113.27	115.74	116.11	116.5	118.96	121.43	128.28	128.76	132.32	134.75	136.55	136.72	136.93	165.94	177.38	189.19
-4.45	-6.89	-11.04	-14.53	-16.21	-18.18	-16.56	-18.65	-19.95	-19.24	-23.19	-46.14	-58.6	-61.15	-63.65	-73.23	-76.89	-79.08	-81.79	-86.77	-88.79	-93.56	-98.87	-105.35	-106.87	-107.28	-110.72	-111.73	-112.8	-117.85	-125.09	-128.03	-129.12	-129.39	-131.46	-135.89	-140.7	-165.3	-186.98
0	0	0	0	0	0	0	0	0	0	0	0	0	0	-0.36	-0.55	-0.64	-0.64	-0.63	-0.47	-0.45	0.2	1.66	0.01	0.7	0.76	0.72	0.77	0.63	0.48	0.17	0.22	0.35	0.2	0.27	0.25	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	20	0	0	0	0	0	0	0	0	0	0	0	0	0
-2.35	-3.84	-7.76	-7.86	-8.57	-10.13	2.53	7.43	23.64	25.46	33.67	13.56	12.06	9.72	2.69	4.55	3.3	1.69	13.06	22.03	20.89	18.53	16.01	8.21	9.87	9.91	6.81	8.36	9.65	11.37	4.3	4.52	5.99	7.37	5.54	1.31	25.5	12.11	2.23
0	0	0	0	0	0	0	0	0	0	0	2.19	0.91	0.84	1.42	0.82	0.91	0.66	0.61	1.59	0.59	1.14	0.83	0.22	0.42	0.42	0.53	0.55	0.55	0.62	0.21	0.25	0.39	0.27	0.84	0.27	1.76	1.62	1.07
0.97	1.07	2.32	3.9	3.81	4.69	1.06	1.82	1.67	2.74	2.88	3.99	5.16	4.04	2.43	1.81	1.1	1.46	3.39	2.67	3.07	2.92	2.69	2.8	2.72	1.94	2.32	1.33	1.49	1.85	1.89	1.9	1.17	1.1	1.62	0.34	1.68	3.92	4.11
0.34	0.3	0.2	0.06	0.06	0.09	0.58	0.49	1.03	1.75	2.31	1.53	2.25	0.65	0.8	1.58	2.01	1.23	1.72	1.83	3.65	3.32	1.68	0.68	0.82	0.6	0.73	1.37	0.91	2.42	1.88	1.35	3.95	1.61	0.88	0.22	0.25	0.36	0.19
0	0	0	0	0	0	0	0	0	0	1.36	5.06	0	0	0.08	0.14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.75	1.21
0.32	1.54	5.17	4.97	5.9	6.43	0.42	0.24	0.24	0.47	0	0	0.05	0.21	0.74	0.58	0.17	0.27	0.21	0.77	1.14	0.35	0.01	0.01	0.3	0.38	0.29	0.14	0.66	2.2	1.15	3.14	5.24	1.05	2.76	1.52	0	0	0
1.63	2.91	7.69	8.93	9.77	11.21	2.06	2.55	2.94	4.96	6.55	12.77	8.37	5.74	5.47	4.93	4.19	3.62	5.93	6.86	8.45	7.73	5.21	3.71	4.26	3.34	3.87	3.39	3.61	7.09	5.13	6.64	10.75	4.03	6.1	2.35	3.69	7.65	6.57
1.01	1.35	3.13	1.29	0.82	0.8	0	0.02	0.16	0.01	0	0	0.18	0.38	7.67	7.99	4.55	4.45	1.18	0.12	0.37	0.02	0	0.03	0.17	0.11	0.16	0.1	1.02	3.17	6.5	5.38	0.17	2.77	0.02	0.53	0	1.21	6.77
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0.15	0	0	0	0	0	0.17	0.49	0.82	1.23	5.51	2.99	2.33	1.93	1.84	0.89	0.65	0.45	0.37	0.32	0.25	0.09	0.18	0.45	0.22	1.27	1.28	1.63	1.08	0.93	0.6	0.12	1.15	2.92	0	2.35	1.31	33.55
1.01	1.5	3.13	1.29	0.82	0.8	0	0.19	0.65	0.83	1.23	5.51	3.17	2.71	9.6	9.83	5.44	5.1	1.63	0.49	0.69	0.27	0.09	0.21	0.62	0.33	1.43	1.38	2.65	4.25	7.43	5.98	0.29	3.92	2.94	0.53	2.35	2.52	40.33
2.64	4.41	10.82	10.22	10.59	12.01	2.06	2.74	3.59	5.79	7.78	18.28	11.54	8.45	15.07	14.76	9.63	8.72	7.56	7.35	9.14	8	5.3	3.92	4.88	3.67	5.3	4.77	6.26	11.34	12.56	12.62	11.04	7.95	9.04	2.88	6.04	10.17	46.9
0.29	0.57	3.06	2.36	2.02	1.88	4.59	10.17	27.23	31.25	41.45	31.84	23.6	18.17	17.76	19.31	12.93	10.41	20.62	29.38	30.03	26.53	21.31	12.13	14.75	13.58	12.11	13.13	15.91	22.71	16.86	17.14	17.03	15.32	14.58	4.19	31.54	22.28	49.13

Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Eterna Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Eterna Therapeutics's financial health and stability.

Assets

Eterna Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Eterna Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Eterna Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Eterna Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

NET INCOME (k)DEPRECIATION AND AMORTIZATION MDEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)Net Cash Flow from Operating Activities (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET DEBT CHANGE (M)Net change in equity (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM FINANCING ACTIVITIES (M)OTHER ITEMS OF FINANCING CASH FLOWS ()CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)

1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-3,000	-1,000	-1,000	1,000	-2,000	-1,000	0	-3,000	-22,000	-12,000	-1,000	-2,000	-9,000	-3,000	-2,000	-2,000	-4,000	-2,000	-4,000	-5,000	-6,000	-1,000	0	-3,000	-1,000	-1,000	-5,000	-7,000	-2,000	-1,000	0	-2,000	-4,000	-122,000	-24,000	-21,000
0	0	0	0	0	0	0	1	2	5	6	6	6	5	4	3	3	3	4	3	3	3	3	3	2	2	2	3	2	2	2	2	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	-1	-6	-2	-1	8	-1	-1	-1	1	-1	-2	0	-1	0	0	0	0	0	0	0	0	0	0	0	0	2	-2	0	-1	-2	3	-2
0	0	0	-3	0	0	-2	0	6	7	-1	-1	2	1	0	0	2	1	6	0	1	0	0	0	0	0	-3	0	0	-3	1	2	0	101	0	3
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-2	-3	-7	-5	-5	-6	-1	1	0	0	1	1	1	-1	3	5	0	-2	2	2	0	2	1	-6	-4	0	0	1	2	-3	-23	-20	-20
0	0	0	0	0	-1	-1	-4	-6	-4	-3	-6	-8	-1	-1	-2	-2	-1	-1	-1	-3	-3	-2	-2	-2	-2	-1	-1	0	-1	-1	-1	0	0	0	0
0	0	0	0	0	-5	1	-1	7	-3	-1	-5	-7	-1	-1	-2	-5	-4	-2	1	-2	-3	-2	-2	-2	-2	-1	-1	0	-1	-1	-1	0	-22	0	0
0	0	0	0	1	-4	3	2	13	1	1	0	1	0	0	0	-3	-2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	1	-22	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	-1	0	0	0	1	3	-5	0	1	0	-2	0	-1	-2	0	-1	0	0	0	0	0	0	1	3	2	0	-3	-1	-1	0	0	0	16
0	0	0	6	6	17	1	11	-2	7	0	0	7	0	0	5	13	0	0	0	0	0	0	0	2	2	6	0	2	1	1	0	0	62	19	0
0	0	0	4	5	15	-1	10	-1	2	0	1	8	-1	0	3	10	0	0	0	0	0	0	0	1	3	10	1	3	-1	0	-1	0	61	19	16
-	-	-	-	-	-2.00	-2.00	-2.00	-2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	1	3	1	-4	4	0	-1	0	-3	1	0	0	1	4	0	2	1	-6	0	0	-2	1	2	1	-3	2	-2	0	0	-2	15	-1	-3
-0.78	-0.39	-0.46	-3.12	-3.66	-9.31	-6.91	-9.33	-12.87	-5.72	-1.65	-6	-8.35	0.21	-0.39	-0.94	-3.59	1.27	4.2	-1.96	-5.96	-0.64	0.63	-2.3	-0.67	-0.96	-8.29	-5.81	-0.82	-0.9	-0.24	1.65	-4.16	-23.64	-21.28	-20.43
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Eterna Therapeutics stock margins US1140822099 ·

The Eterna Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eterna Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eterna Therapeutics.

3 years
5 years
10 years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eterna Therapeutics's sales revenue. A higher gross margin percentage indicates that the Eterna Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eterna Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eterna Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eterna Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eterna Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eterna Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eterna Therapeutics Margin History

Eterna Therapeutics Gross margin	Eterna Therapeutics Profit margin	Eterna Therapeutics EBIT margin	Eterna Therapeutics Profit margin
2023	-247.06 %	-30,404.41 %	-31,888.23 %
2022	-247.06 %	0 %	0 %
2021	-247.06 %	0 %	0 %
2020	49.83 %	-93.1 %	-76.38 %
2019	62.19 %	-6.11 %	-10.4 %
2018	65.42 %	1.97 %	-1.2 %
2017	68.27 %	-6.58 %	-5.12 %
2016	65.44 %	-10.22 %	-13.09 %
2015	48.74 %	-26.92 %	-29.49 %
2014	57.2 %	-15.62 %	-19.31 %
2013	67.62 %	-3.75 %	-4.42 %
2012	74.44 %	-4.36 %	-4.16 %
2011	75.66 %	-13.07 %	-14.33 %
2010	76.06 %	-0.36 %	-1.58 %
2009	74.97 %	-5.19 %	-5.81 %
2008	72.4 %	-20.4 %	-23.53 %
2007	70.5 %	-9.53 %	-16.47 %
2006	69.6 %	3.73 %	-14.46 %
2005	67.93 %	0.26 %	-6.57 %
2004	67.39 %	-9.13 %	-18.95 %

	Gross margin	EBIT margin	Profit margin
2004	67.39 %	-9.13 %	-18.95 %
2005	67.93 %	0.26 %	-6.57 %
2006	69.6 %	3.73 %	-14.46 %
2007	70.5 %	-9.53 %	-16.47 %
2008	72.4 %	-20.4 %	-23.53 %
2009	74.97 %	-5.19 %	-5.81 %
2010	76.06 %	-0.36 %	-1.58 %
2011	75.66 %	-13.07 %	-14.33 %
2012	74.44 %	-4.36 %	-4.16 %
2013	67.62 %	-3.75 %	-4.42 %
2014	57.2 %	-15.62 %	-19.31 %
2015	48.74 %	-26.92 %	-29.49 %
2016	65.44 %	-10.22 %	-13.09 %
2017	68.27 %	-6.58 %	-5.12 %
2018	65.42 %	1.97 %	-1.2 %
2019	62.19 %	-6.11 %	-10.4 %
2020	49.83 %	-93.1 %	-76.38 %
2021	-247.06 %	0 %	0 %
2022	-247.06 %	0 %	0 %
2023	-247.06 %	-30,404.41 %	-31,888.23 %

Eterna Therapeutics Stock Sales Revenue, EBIT, Earnings per Share US1140822099 ·

The Eterna Therapeutics earnings per share therefore indicates how much revenue Eterna Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 years
5 years
10 years
25 Years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Eterna Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Eterna Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Eterna Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Eterna Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eterna Therapeutics Revenue, EBIT and net profit per share

Date	Eterna Therapeutics Sales per Share	Eterna Therapeutics EBIT per share	Eterna Therapeutics Earnings per Share
2023	0.01 undefined	-3.89 undefined	-4.08 undefined
2022	0 undefined	-8.93 undefined	-8.07 undefined
2021	0 undefined	-12.64 undefined	-56.48 undefined
2020	82.86 undefined	-77.14 undefined	-63.29 undefined
2019	283 undefined	-17.29 undefined	-29.43 undefined
2018	333.43 undefined	6.57 undefined	-4 undefined
2017	354.5 undefined	-23.33 undefined	-18.17 undefined
2016	446.2 undefined	-45.6 undefined	-58.4 undefined
2015	490.4 undefined	-132 undefined	-144.6 undefined
2014	651.25 undefined	-101.75 undefined	-125.75 undefined
2013	593.75 undefined	-22.25 undefined	-26.25 undefined
2012	802 undefined	-35 undefined	-33.33 undefined
2011	795.67 undefined	-104 undefined	-114 undefined
2010	843.67 undefined	-3 undefined	-13.33 undefined
2009	860.33 undefined	-44.67 undefined	-50 undefined
2008	916.67 undefined	-187 undefined	-215.67 undefined
2007	1,018 undefined	-97 undefined	-167.67 undefined
2006	1,099.67 undefined	41 undefined	-159 undefined
2005	1,025 undefined	2.67 undefined	-67.33 undefined
2004	876 undefined	-80 undefined	-166 undefined

	Sales per Share	EBIT per share	Earnings per Share
2004	876 USD	-80 USD	-166 USD
2005	1,025 USD	2.67 USD	-67.33 USD
2006	1,099.67 USD	41 USD	-159 USD
2007	1,018 USD	-97 USD	-167.67 USD
2008	916.67 USD	-187 USD	-215.67 USD
2009	860.33 USD	-44.67 USD	-50 USD
2010	843.67 USD	-3 USD	-13.33 USD
2011	795.67 USD	-104 USD	-114 USD
2012	802 USD	-35 USD	-33.33 USD
2013	593.75 USD	-22.25 USD	-26.25 USD
2014	651.25 USD	-101.75 USD	-125.75 USD
2015	490.4 USD	-132 USD	-144.6 USD
2016	446.2 USD	-45.6 USD	-58.4 USD
2017	354.5 USD	-23.33 USD	-18.17 USD
2018	333.43 USD	6.57 USD	-4 USD
2019	283 USD	-17.29 USD	-29.43 USD
2020	82.86 USD	-77.14 USD	-63.29 USD
2021	0 USD	-12.64 USD	-56.48 USD
2022	0 USD	-8.93 USD	-8.07 USD
2023	0.01 USD	-3.89 USD	-4.08 USD

Eterna Therapeutics business model

Eterna Therapeutics is one of the most popular companies on Eulerpool.com.

Eterna Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Eterna Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Eterna Therapeutics shares outstanding US1140822099 ·

The number of shares was Eterna Therapeutics in 2023 — This indicates how many shares 5.314 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 years
5 years
10 years
25 Years
Max

Number of stocks

Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

	Number of stocks
2004	30,000 Aktien
2005	30,000 Aktien
2006	30,000 Aktien
2007	30,000 Aktien
2008	30,000 Aktien
2009	30,000 Aktien
2010	30,000 Aktien
2011	30,000 Aktien
2012	30,000 Aktien
2013	40,000 Aktien
2014	40,000 Aktien
2015	50,000 Aktien
2016	50,000 Aktien
2017	60,000 Aktien
2018	70,000 Aktien
2019	70,000 Aktien
2020	70,000 Aktien
2021	2.17 M Aktien
2022	3.05 M Aktien
2023	5.31 M Aktien

Eterna Therapeutics Stock splits

In Eterna Therapeutics's history, there have been no stock splits.

Unfortunately, there are currently no price targets and forecasts available for Eterna Therapeutics.

Eterna Therapeutics latest earnings and earnings surprises

Date	EPS Estimate	EPS Actual	Quarterly report
9/30/2023	0	-1.03 (0 %)	2023 Q3
9/30/2022	-2.24	-2.49 (-10.96 %)	2022 Q3
6/30/2022	-2.65	-1.2 (54.75 %)	2022 Q2
3/31/2022	-2.86	-3.4 (-19.05 %)	2022 Q1
12/31/2021	-2.55	-3.2 (-25.49 %)	2021 Q4
9/30/2021	-1.63	-2.2 (-34.8 %)	2021 Q3
12/31/2018	6.12	4.4 (-28.1 %)	2018 Q4
9/30/2018	-1.63	3.2 (296.08 %)	2018 Q3
6/30/2018	-9.38	-2 (78.69 %)	2018 Q2
3/31/2018	-11.02	-6.4 (41.9 %)	2018 Q1
12/31/2017	-5.71	-10 (-75.07 %)	2017 Q4
9/30/2017	-8.57	-2.8 (67.32 %)	2017 Q3
6/30/2017	-14.28	-2.8 (80.39 %)	2017 Q2
3/31/2017	-15.91	-1.6 (89.94 %)	2017 Q1
12/31/2016	-7.75	-8.8 (-13.52 %)	2016 Q4
9/30/2016	-19.58	-12.4 (36.68 %)	2016 Q3
6/30/2016	-21.22	-18.4 (13.27 %)	2016 Q2
3/31/2016	-40.8	-22.4 (45.1 %)	2016 Q1
12/31/2015	-20.4	-20 (1.96 %)	2015 Q4
9/30/2015	-40.8	-20 (50.98 %)	2015 Q3
6/30/2015	-61.2	-60 (1.96 %)	2015 Q2
9/30/2007	-20.4	-60 (-194.12 %)	2007 Q3
6/30/2007	-40.8	-20 (50.98 %)	2007 Q2
3/31/2007	-40.8	-20 (50.98 %)	2007 Q1
12/31/2006	0	0 (0 %)	2006 Q4
9/30/2006	-6.79	0 (100 %)	2006 Q3
6/30/2006	0	-60 (0 %)	2006 Q2
3/31/2006	6.79	0 (-100 %)	2006 Q1
12/31/2005	20.4	0 (-100 %)	2005 Q4
9/30/2005	-20.4	0 (100 %)	2005 Q3
6/30/2005	-40.8	-40 (1.96 %)	2005 Q2
3/31/2005	-40.8	-40 (1.96 %)	2005 Q1
12/31/2004	-40.8	-60 (-47.06 %)	2004 Q4
3/31/2004	-40.8	-40 (1.96 %)	2004 Q1
12/31/2003	-40.8	-40 (1.96 %)	2003 Q4
6/30/2002	-81.6	-40 (50.98 %)	2002 Q2
12/31/1997	-163.2	-260 (-59.31 %)	1997 Q4

Eulerpool ESG Scorecard© for the Eterna Therapeutics stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Scope 1 - Direct Emissions	—
Scope 2 - Indirect emissions from purchased energy	—
Scope 3 - Indirect emissions within the value chain	—
Total CO₂ emissions	—
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	✅
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	❌
Environmentally friendly packaging	❌
Hazardous substances	❌
Fuel consumption and efficiency	❌
Water consumption and efficiency	❌

Social

Percentage of female employees	—
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	❌
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Governance (Corporate Governance)

Environmental reporting	❌
Stakeholder Engagement	❌
Call Back Policies	❌
Antitrust law	❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Eterna Therapeutics list of shareholders

%	Name	Stocks	Change	Date
9.63 %	Lake Street Advisors	520,996	520,996	12/31/2023
8.46 %	Denny George P Iii	457,442	204	3/12/2024
8.36 %	Halpern (John D)	452,284	0	3/12/2024
5.04 %	Freebird Partners LP	272,583	0	3/12/2024
3.93 %	IAF, LLC	212,464	0	3/12/2024
3.23 %	Angel (Matthew)	174,482	125,832	3/12/2024
10.29 %	Cherington (Charles)	556,465	0	3/12/2024
1.74 %	Cypress Point Wealth Management, LLC	94,375	0	12/31/2023
1.46 %	Naviter Wealth, LLC	78,796	0	3/31/2024
1.00 %	Sippican Capital Advisors LLC	54,050	25,950	12/31/2023
0.93 %	Corient Private Wealth LLC	50,398	-914	12/31/2023
0.48 %	The Vanguard Group, Inc.	26,099	1,201	12/31/2023
0.42 %	Geode Capital Management, L.L.C.	22,488	0	12/31/2023
0.29 %	BlackRock Institutional Trust Company, N.A.	15,619	-958	12/31/2023
0.16 %	Baldwin Brothers, LLC.	8,544	0	3/31/2024
0.08 %	Tower Research Capital LLC	4,409	-195	12/31/2023
0.02 %	Gurrola Sandra M	928	0	3/12/2024
0.00 %	Mackenzie Financial Corporation	80	-11	9/30/2022
0.00 %	MONTAG Wealth Management	70	0	12/31/2023
0.00 %	Morgan Stanley Smith Barney LLC	50	0	12/31/2023
0.00 %	RBC Capital Partners	31	0	12/31/2023
0.00 %	Wells Fargo Bank, N.A.	28	2	12/31/2023
0.00 %	Group One Trading, L.P.	19	0	12/31/2023
0.00 %	Citi Investment Research (US)	15	0	12/31/2023
0.00 %	J.P. Morgan Securities plc	14	0	12/31/2023
0.00 %	NBC Securities, Inc.	10	10	3/31/2024
0.00 %	Aspire Private Capital, LLC	10	0	3/31/2024
0.00 %	Guggenheim Investments	8	0	11/30/2023
0.00 %	Qube Research & Technologies Ltd	4	0	12/31/2023
0.00 %	Fidelity Management & Research Company LLC	1	0	12/31/2023
0 %	AJ Wealth Strategies, LLC	0	-36,001	3/31/2023
0 %	Susquehanna Fundamental Investments, LLC	0	-1,612	9/30/2022
0 %	Carmichael Hill & Associates Inc	0	-75	9/30/2023
0 %	Ergoteles Capital	0	-7,275	9/30/2022
0 %	Athena Investment Management	0	-1,778	9/30/2022
0 %	Simplex Trading, LLC	0	-417	9/30/2022
0 %	AHL Partners LLP	0	-2,112	12/31/2022
0 %	Cubist Systematic Strategies, LLC	0	-1,200	12/31/2022
0 %	Ground Swell Capital, LLC	0	-681	9/30/2022
0 %	Armistice Capital LLC	0	-55,490	12/31/2022
0 %	LMR Partners LLP	0	-705	9/30/2022
0 %	BlackRock Asset Management Ireland Limited	0	-1,126	12/31/2022
0 %	Assenagon Asset Management S.A.	0	-1,838	12/31/2022
0 %	Virtu Americas LLC	0	-3,156	12/31/2022
0 %	Credit Suisse International	0	-1	9/30/2022
0 %	Allegheny Financial Group Ltd.	0	-580	12/31/2022
0 %	China Universal Asset Management Co., Ltd.	0	-28	12/31/2022
0 %	Jane Street Capital, L.L.C.	0	-1,010	9/30/2022
0 %	GF Fund Management Co., Ltd.	0	-27	12/31/2022
0 %	Susquehanna International Group, LLP	0	-1,711	12/31/2022
0 %	Two Sigma Investments, LP	0	-8,839	12/31/2022
0 %	Morgan Stanley & Co. International Plc	0	-34	12/31/2022
0 %	Wells Fargo Advisors	0	-10	3/31/2023
0 %	Millennium Management LLC	0	-41,844	12/31/2022
0 %	Russell Investments Limited	0	-632	8/31/2022
0 %	ProFund Advisors LLC	0	-32	7/31/2022
0 %	Rafferty Asset Management LLC	0	-4,414	9/30/2022
0 %	Renaissance Technologies LLC	0	-13,053	6/30/2023
0 %	Bridgeway Capital Management, LLC	0	-635	12/31/2022
0 %	Citadel Advisors LLC	0	-2,529	12/31/2022
0 %	BlackRock Japan Co., Ltd.	0	-305	9/30/2022
0 %	BlackRock Investment Management (UK) Ltd.	0	-1,301	9/30/2022
0 %	JPMorgan Asset Management U.K. Limited	0	-4,135	12/31/2022
0 %	BlackRock Advisors (UK) Limited	0	-1,180	12/31/2022
0 %	State Street Global Advisors (US)	0	-4,600	12/31/2022
0 %	BlackRock Financial Management, Inc.	0	-17,387	9/30/2022
0 %	Morgan Stanley Investment Management Inc. (US)	0	-17	9/30/2022
0 %	Morgan Stanley & Co. LLC	0	-1,312	3/31/2023
0 %	BofA Global Research (US)	0	-9	6/30/2023
0 %	BlackRock Investment Management, LLC	0	-476	6/30/2023
0 %	BNY Mellon Wealth Management	0	-2,096	12/31/2022
0 %	Goldman Sachs & Company, Inc.	0	-11,284	9/30/2023
0 %	Credit Suisse Securities (USA) LLC	0	-120	3/31/2023
0 %	Eagle Asset Management, Inc.	0	-3,590	12/31/2022
0 %	Dimensional Fund Advisors, L.P.	0	-46	11/30/2023
0 %	RBC Capital Markets Wealth Management	0	-159	12/31/2022
0 %	BNY Mellon Asset Management	0	-386	12/31/2022
0 %	Northern Trust Investments, Inc.	0	-2,457	12/31/2022
0 %	Goldman Sachs Asset Management, L.P.	0	-911	9/30/2022
0 %	New York State Common Retirement Fund	0	-12	9/30/2022
0 %	UBS Financial Services, Inc.	0	-105	12/31/2023
0 %	Purchase Capital LLC	0	-121,822	12/31/2023
0 %	Singer (Nicholas Jason)	0	-266,214	12/31/2023
0 %	Harvest Volatility Management LLC	0	-10	7/31/2022

...

Most common questions regarding Eterna Therapeutics

What is the P/E ratio of Eterna Therapeutics 2024?

The P/E ratio cannot be calculated for Eterna Therapeutics at the moment.

What is the P/S ratio of Eterna Therapeutics 2024?

The P/S cannot be calculated for Eterna Therapeutics currently.

What is the AlleAktien quality score of Eterna Therapeutics?

The AlleAktien quality score for Eterna Therapeutics is 3/10.

What is the revenue of Eterna Therapeutics 2024?

The revenue cannot currently be calculated for Eterna Therapeutics.

How high is the profit of Eterna Therapeutics 2024?

The profit cannot currently be calculated for Eterna Therapeutics.

What is the business model of Eterna Therapeutics

No history available for Eterna Therapeutics.

What is the Eterna Therapeutics dividend?

Eterna Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Eterna Therapeutics pay dividends?

The dividend cannot currently be calculated for Eterna Therapeutics or the company does not pay out a dividend.

What is the Eterna Therapeutics ISIN?

The ISIN of Eterna Therapeutics is US1140822099.

What is the Eterna Therapeutics ticker?

The ticker of Eterna Therapeutics is ERNA.

How much dividend does Eterna Therapeutics pay?

Over the past 12 months, Eterna Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eterna Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Eterna Therapeutics?

The current dividend yield of Eterna Therapeutics is .

When does Eterna Therapeutics pay dividends?

Eterna Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eterna Therapeutics?

Eterna Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Eterna Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eterna Therapeutics located?

Eterna Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eterna Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eterna Therapeutics from 8/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/9/2024.

When did Eterna Therapeutics pay the last dividend?

The last dividend was paid out on 8/9/2024.

What was the dividend of Eterna Therapeutics in the year 2023?

In the year 2023, Eterna Therapeutics distributed 0 USD as dividends.

In which currency does Eterna Therapeutics pay out the dividend?

The dividends of Eterna Therapeutics are distributed in USD.

Eterna Therapeutics stock price, news, forecast, analysis

Sector

Health

Industry

Biotechnology

Number of shares

5,410,000

Employee

Revenue growth Ø5 years

-67.85 %

EBIT growth Ø5 years

76.41 %

Net Income growth Ø5 years

60.12 %

Website Eterna Therapeutics

Country

United States of America 🇺🇸

Currency

USD

Initial public offering

Aug 29, 1991

GOSIN

Global Open Securities Identification Number

Cusip

114082209

Market capitalization

9.96 M

Eterna Therapeutics Directors Dealings

AAQS

Details

3 / 10

PEG

P/E

Forward P/E

P/S

Forward P/S

ROE (Return on Equity)

-971.07 %

ROA (Return on Assets)

-44.13 %

ROCE (Return on Capital Employed)

-48.58 %

ROIC

Scalable Capital savings plan

Nein

Trade Republic savings plan

Nein

comdirect savings plan

Consorsbank savings plan

Nein

ING savings plan

Nein

Eterna Therapeutics Peer Group

Eterna Therapeutics Eulerpool News

Eterna Therapeutics News

All Eterna Therapeutics News

Eterna Therapeutics Ticker

Stock Exchange	Eterna Therapeutics Ticker
NASDAQ	ERNA

Eterna Therapeutics FIGI

Eterna Therapeutics Ticker	Eterna Therapeutics FIGI
ERNA:US	BBG000CX5677
ERNA:UA	BBG000CX56R5
ERNA:UC	BBG000CX5766
ERNA:UN	BBG000CX69F1
ERNA:UP	BBG000CX6B02
ERNA:UB	BBG000CX6BR3
ERNA:UM	BBG000CX6CM6
ERNA:UX	BBG000CX6D17
ERNA:UR	BBG000CX6DZ0
ERNA:UD	BBG000CX6H90
ERNA:UF	BBG000CX6JQ7
ERNA:VY	BBG000CX6KB0
ERNA:VJ	BBG000CX6KP5
ERNA:VK	BBG000CX6L64
ERNA:VF	BBG00DJD5NB4

All fundamentals about Eterna Therapeutics

Our stock analysis for Eterna Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eterna Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

TickerERNA

ISINUS1140822099

Eterna Therapeutics stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Eterna Therapeutics Stock Price History

Eterna Therapeutics Revenue, EBIT, Net Income US1140822099 ·

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Eterna Therapeutics Revenue, EBIT and net profit per share

Eterna Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Eterna Therapeutics stock margins US1140822099 ·

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Eterna Therapeutics Margin History

Eterna Therapeutics Stock Sales Revenue, EBIT, Earnings per Share US1140822099 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Eterna Therapeutics Revenue, EBIT and net profit per share

Eterna Therapeutics business model

Eterna Therapeutics Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Eterna Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Eterna Therapeutics shares outstanding US1140822099 ·

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Eterna Therapeutics Stock splits

Eterna Therapeutics Earnings Estimates

Eterna Therapeutics latest earnings and earnings surprises

Eulerpool ESG Scorecard© for the Eterna Therapeutics stock

Eulerpool World ESG Rating (EESG©)

71/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Social

Governance (Corporate Governance)

Eterna Therapeutics list of shareholders

Most common questions regarding Eterna Therapeutics

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
ERNA

ISIN
US1140822099